ArticleFrontiers in pediatrics2025
Prenatal dexamethasone exposure and the risk of early-onset sepsis in preterm infants.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gestational age-specific effects of antenatal corticosteroids on early physiologic vulnerability and neonatal outcomes.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Robust evidence has consistently demonstrated the impact of antenatal corticosteroid (ACS) administration on reducing mortality and improving short-term neonatal outcomes in singleton preterm infants. However, its effect on neonatal sepsis, particularly early-onset sepsis (EOS), remains poorly understood and requires further investigation. This study aimed to evaluate the potential association between prenatal dexamethasone exposure (PDE) and incidence of EOS in preterm infants. Methods: This retrospective, single-center observational study included singleton preterm neonates with a gestational age less than 32 weeks or a birth weight below 1,500 g between 2022 and 2024. Participates were stratified into four groups based on PDE: no PDE, partial PDE (1-3 doses), PDE 1-7 days (complete course with delivery within 7 days of administration), and PDE ≥8 days (complete course with delivery more than 7 days after administration). The primary outcome was the incidence of EOS, while secondary outcomes encompassed other short-term neonatal complications. Results: The analysis revealed that neonates in the PDE 1-7 days group demonstrated a significantly reduced incidence of EOS compared with the no PDE group [adjusted odds ratio[aOR]: 0.299, 95% confidence interval [95%CI]: 0.122-0.731]. Furthermore, this group exhibited superior outcomes, including lower rates of respiratory distress syndrome (RDS), reduced the need for surfactant treated in RDS cases, and decreased extrauterine growth restriction (EUGR). Notably, the PDE ≥8 days group was associated with an elevated risk of EOS when compared with the PDE 1-7 days group. Conclusion: PDE, particularly when a complete course is administered 1-7 days prior to delivery, demonstrates a significant protective effect against EOS in preterm infants. Nevertheless, large-scale multicenter prospective studies are warranted to further validated these findings and to comprehensively evaluate the long-term neurodevelopmental and systemic outcomes associated with PDE administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.